209 results
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
Galapagos’ efforts and ensure consistent quality.
Galapagos’ innovative, decentralized manufacturing platform could address many of the limitations … ’ decentralized, innovative CAR-T manufacturing platform has the potential for the administration of fresh, fit cells within a median vein-to-vein time of seven
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
our innovative decentralized CAR-T manufacturing and 7-day vein-to-vein approach to hematological cancer care at the EBMT-EHA and EBMT annual meetings
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
EXHIBIT 99.1
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT … in patients with relapsed/refractory NHL, CLL and RT, combined with our unique, innovative decentralized manufacturing approach that enables a seven-day vein
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
molecules, CAR-T therapies and biologics in oncology and immunology. We continue to take steps to transform into an innovative pure-play biotech … experience. This innovative platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
billion upfront payment from Gilead Sciences, and (ii) Gilead Sciences gained exclusive access and certain rights to the Company’s innovative portfolio … on developing innovative medicines for life-threatening diseases. Simultaneously with the execution of the Subscription Agreement, the Company
6-K
EX-99.1
qzt4 upghl
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
x47oqubelnj7 qh787
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
267kp6
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
t8vjv
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
79l4n 7bk
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
tpcgy4k
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
k33g1gnvtcgc0
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
ow2ub2 ytzo19laiqle
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
1hvs9sjux4shrw44
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
4dw dpe7nl
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
qioaoec n3yv05
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
gp8t ujxprejsbx
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
859tqwc6i 1kce
9 May 23
Galapagos creates new subscription right plans
5:02pm
6-K
EX-99.1
k2jf02ch ir8dm9
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm